AR095594A1 - Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos - Google Patents
Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticosInfo
- Publication number
- AR095594A1 AR095594A1 ARP140101219A ARP140101219A AR095594A1 AR 095594 A1 AR095594 A1 AR 095594A1 AR P140101219 A ARP140101219 A AR P140101219A AR P140101219 A ARP140101219 A AR P140101219A AR 095594 A1 AR095594 A1 AR 095594A1
- Authority
- AR
- Argentina
- Prior art keywords
- overweight
- antibiotics
- methods
- patients
- obesos
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente divulgación se refiere de manera general a métodos para tratar infecciones en pacientes con sobrepeso u obesos usando antibióticos. Reivindicación 40: El método de la reivindicación 39, donde el compuesto es delafloxacina. Reivindicación 41: El método de cualquiera de las reivindicaciones anteriores, donde la dosificación está comprendida entre aproximadamente 10 mg/día y aproximadamente 600 mg/día.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361790179P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095594A1 true AR095594A1 (es) | 2015-10-28 |
Family
ID=51581190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140101219A AR095594A1 (es) | 2013-03-15 | 2014-03-17 | Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos |
Country Status (14)
Country | Link |
---|---|
US (3) | US12036219B2 (es) |
EP (1) | EP2969004A4 (es) |
JP (2) | JP6617097B2 (es) |
KR (1) | KR102237887B1 (es) |
AR (1) | AR095594A1 (es) |
AU (2) | AU2014239965A1 (es) |
BR (1) | BR112015023044A8 (es) |
CA (1) | CA2904387C (es) |
CL (1) | CL2015002759A1 (es) |
HK (1) | HK1219690A1 (es) |
IL (1) | IL241113A0 (es) |
MX (1) | MX2015011760A (es) |
TW (1) | TWI641372B (es) |
WO (1) | WO2014152332A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201605447A (zh) * | 2014-06-20 | 2016-02-16 | 美林塔治療學有限公司 | 處理感染的方法 |
WO2016137806A2 (en) | 2015-02-23 | 2016-09-01 | Theravance Biopharma Antibiotics Ip, Llc | Doses and methods of administering telavancin |
CN107216353B (zh) * | 2016-03-21 | 2020-05-19 | 山东诚创医药技术开发有限公司 | 一种头孢洛林酯咪唑盐的精制方法 |
JP2019527214A (ja) | 2016-07-14 | 2019-09-26 | アカオジェン インコーポレイテッド | 細菌感染症の処置における使用のためのセフチブテンとクラブラン酸の組み合わせ |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO156828C (no) | 1980-11-10 | 1987-12-02 | Otsuka Pharma Co Ltd | Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser. |
DK170473B1 (da) | 1985-06-20 | 1995-09-11 | Daiichi Seiyaku Co | S(-)-pyridobenzoxazinforbindelser |
JPH089597B2 (ja) | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法 |
CA1315229C (en) | 1987-06-10 | 1993-03-30 | Patrick J. Baker | Chromatographic purification process |
DE3906365A1 (de) | 1988-07-15 | 1990-01-18 | Bayer Ag | 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe |
ATE146783T1 (de) | 1991-11-01 | 1997-01-15 | Upjohn Co | Substituierte aryl- und heteroaryl- phenyloxazolidinone |
US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
MY128335A (en) | 1994-01-28 | 2007-01-31 | Lilly Co Eli | Glycopeptide antibiotic derivatives |
EP0688772B1 (en) | 1994-06-16 | 1999-05-06 | LG Chemical Limited | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituents and processes for their preparation |
US5776944A (en) | 1994-06-16 | 1998-07-07 | Lg Chemical Ltd. | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
KR100371723B1 (ko) | 1994-08-12 | 2003-03-15 | 도야마 가가쿠 고교 가부시키가이샤 | 신규한퀴놀론-또는나프틸리돈-카복실산유도체또는그의염 |
JP3449658B2 (ja) | 1994-12-21 | 2003-09-22 | 杏林製薬株式会社 | 安定性に優れた8−アルコキシキノロンカルボン酸水和物並びにその製造方法 |
CA2232728C (en) | 1995-09-22 | 2003-11-04 | Wakunaga Pharmaceutical Co., Ltd. | Novel pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components |
DE19546249A1 (de) | 1995-12-12 | 1997-06-19 | Bayer Ag | Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen |
CA2242242C (en) | 1996-02-09 | 2001-08-07 | Toyama Chemical Co., Ltd. | Quinolonecarboxylic acid derivatives or salts thereof |
US5939382A (en) | 1996-11-21 | 1999-08-17 | Eli Lilly And Company | Reducing agent for reductive alkylation of glycopeptide antibiotics |
US5952466A (en) | 1997-11-12 | 1999-09-14 | Eli Lilly And Company | Reductive alkylation of glycopeptide antibiotics |
ID18900A (id) | 1996-11-21 | 1998-05-20 | Lilly Co Eli | Alkilasi menurun dari gliko peptida anti biotik |
US20020032216A1 (en) | 1997-03-21 | 2002-03-14 | Lg Chemical Ltd. | Salt of naphthyridine carboxylic acid derivative |
US5994297A (en) | 1997-08-22 | 1999-11-30 | Eli Lilly And Company | Therapy for Staphylococcus aureus |
US6518242B1 (en) | 1998-02-20 | 2003-02-11 | Theravance, Inc. | Derivatives of glycopeptide antibacterial agents |
CA2344318C (en) | 1998-09-25 | 2006-07-04 | Cubist Pharmaceuticals, Inc. | Methods for administration of antibiotics |
SI1140993T1 (en) | 1998-12-23 | 2003-12-31 | Theravance, Inc. | Glycopeptide derivatives and pharmaceutical compositions containing the same |
HUP0200940A3 (en) | 1999-05-03 | 2002-10-28 | Lilly Co Eli | Use of glycopeptide antibiotic for treatment of streptococcus pneumoniae infections and pharmaceutical compositions containing them |
US6750224B1 (en) | 1999-05-07 | 2004-06-15 | Wockhardt Limited | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment |
US6331550B1 (en) | 1999-06-29 | 2001-12-18 | Smithkline Beecham Corporation | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
US6262071B1 (en) | 1999-06-29 | 2001-07-17 | Smithkline Beecham Corporation | Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria |
US6803376B1 (en) | 1999-06-29 | 2004-10-12 | Smithkline Beecham Corporation | Method of use of quinolone compounds against pneumococcal and haemophilus bacteria |
CA2282066C (en) | 1999-06-29 | 2010-09-07 | Smithkline Beecham Corporation | Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria |
JP2005097116A (ja) | 1999-11-11 | 2005-04-14 | Wakunaga Pharmaceut Co Ltd | キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法 |
US6514986B2 (en) | 2000-11-22 | 2003-02-04 | Wockhardt Limited | Chiral fluoroquinolone arginine salt forms |
US6444813B2 (en) | 2000-02-02 | 2002-09-03 | Pharmacia & Upjohn Company | Linezolid-crystal form II |
EP1262477B1 (en) | 2000-02-09 | 2008-09-03 | Daiichi Sankyo Company, Limited | Anti-acid-fast bacterial agents containing pyridonecarboxylic acids as the active ingredient |
CA2408806A1 (en) | 2000-03-31 | 2001-10-04 | Masayasu Sekiguchi | Quinolonecarboxylic acid derivative |
GB0009803D0 (en) | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
US6770621B2 (en) | 2000-05-02 | 2004-08-03 | Theravance, Inc. | Polyacid glycopeptide derivatives |
DE60135102D1 (de) | 2000-05-02 | 2008-09-11 | Theravance Inc | Verfahren zur reduktiven alkylierung von glykopeptiden |
AU2001259306A1 (en) | 2000-05-02 | 2001-11-12 | Advanced Medicine, Inc. | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
US6608078B2 (en) | 2000-05-08 | 2003-08-19 | Wockhardt Limited | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment |
HUP0301562A2 (hu) | 2000-06-05 | 2003-12-29 | Dong A Pharm. Co., Ltd. | Új oxazolidinonszármazékok és eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények |
DE60133198T2 (de) | 2000-06-22 | 2009-03-12 | Theravance, Inc., South San Francisco | Glykopeptidderivate mit carboxysacchariden |
UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
AU2001259816A1 (en) | 2000-06-22 | 2002-01-02 | Advanced Medecine, Inc. | Polyhydroxy glycopeptide derivatives |
US6872804B2 (en) | 2000-06-22 | 2005-03-29 | Theravance, Inc. | Glycopeptide disulfide and thioester derivatives |
ATE544745T1 (de) | 2000-07-07 | 2012-02-15 | Tufts College | 9-substituierte minocyclinverbindungen |
JP2002201191A (ja) | 2000-09-28 | 2002-07-16 | Dai Ichi Seiyaku Co Ltd | キノロンカルボン酸誘導体の製造方法およびその製造中間体 |
ZA200303558B (en) | 2000-11-24 | 2004-09-06 | Meiji Seika Kaisha | Novel carbapenem derivatives. |
JP2002255962A (ja) | 2001-02-26 | 2002-09-11 | Dai Ichi Seiyaku Co Ltd | キノロンカルボン酸誘導体 |
US7553828B2 (en) | 2001-03-13 | 2009-06-30 | Paratek Pharmaceuticals, Inc. | 9-aminomethyl substituted minocycline compounds |
US7045507B2 (en) | 2001-03-14 | 2006-05-16 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds as synergistic antifungal agents |
CA2444899C (en) | 2001-04-24 | 2011-06-21 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
US8088820B2 (en) | 2001-04-24 | 2012-01-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
US6589955B2 (en) | 2001-06-20 | 2003-07-08 | Bristol-Myers Squibb Company | Pediatric formulation of gatifloxacin |
EP2332548A1 (en) | 2001-07-13 | 2011-06-15 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of stroke |
TWI275594B (en) | 2001-08-24 | 2007-03-11 | Theravance Inc | Process for preparing vancomycin phosphonate derivatives |
JP2003096075A (ja) | 2001-09-26 | 2003-04-03 | Dai Ichi Seiyaku Co Ltd | キノロンカルボン酸誘導体の製法 |
WO2003076428A1 (fr) | 2002-03-08 | 2003-09-18 | Daiichi Pharmaceutical Co., Ltd. | Derive d'acide quinolone-carboxylique |
EP1482926A4 (en) | 2002-03-08 | 2006-04-12 | Paratek Pharm Innc | AMINO METHYL SUBSTITUTED TETRACYCLINE COMPOUNDS |
DE10210779A1 (de) | 2002-03-12 | 2003-10-09 | Merck Patent Gmbh | Cyclische Amide |
US6878686B2 (en) | 2002-05-24 | 2005-04-12 | Theravance, Inc. | Cross-linked glycopeptide-cephalosporin antibiotics |
WO2003099815A1 (en) | 2002-05-28 | 2003-12-04 | Wockhardt Limited | Crystalline fluoroquinolone arginine salt form |
EP2277504A1 (en) | 2002-10-24 | 2011-01-26 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
WO2004038000A2 (en) | 2002-10-24 | 2004-05-06 | Paratek Pharmaceuticals, Inc. | Methods of using substituted tetracycline compounds to modulate rna |
US7119061B2 (en) | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
WO2004045637A1 (en) | 2002-11-18 | 2004-06-03 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
US7524951B2 (en) | 2002-12-13 | 2009-04-28 | Meiji Seika Kaisha, Ltd. | Intermediates of 2-substituted carbapenem derivatives and process for production thereof |
US6936651B2 (en) | 2002-12-17 | 2005-08-30 | E. I. Du Pont De Nemours And Company | Compatibility improvement in crystalline thermoplastics with mineral fillers |
JP2006151808A (ja) | 2002-12-24 | 2006-06-15 | Dai Ichi Seiyaku Co Ltd | 抗菌性水性製剤 |
WO2004064728A2 (en) | 2003-01-16 | 2004-08-05 | Paratek Pharmaceuticals, Inc. | Use of specific tetracycline compounds in therapy |
JP2004244380A (ja) | 2003-02-14 | 2004-09-02 | Dai Ichi Seiyaku Co Ltd | キノロンカルボン酸の製造中間体および製造方法 |
WO2004091513A2 (en) | 2003-04-10 | 2004-10-28 | Paratek Pharmaceuticals, Inc. | 9-aminomethyl substituted minocycline compounds |
US20060270680A1 (en) | 2003-06-03 | 2006-11-30 | Goldberg Joel A | Sulfonamide compounds and methods of making and using the same |
ES2393292T3 (es) | 2003-06-03 | 2012-12-20 | Rib-X Pharmaceuticals, Inc. | Compuestos heterocíclicos de biarilo y métodos de obtención y uso de los mismos |
WO2005012271A2 (en) | 2003-07-29 | 2005-02-10 | Rib-X Pharmaceuticals, Inc. | Process for the synthesis of biaryl oxazolidinones |
US20050137174A1 (en) | 2003-07-09 | 2005-06-23 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
JP2007500707A (ja) | 2003-07-29 | 2007-01-18 | リブ−エックス ファーマシューティカルズ,インコーポレイテッド | ビアリールヘテロ環状のアミン、アミドおよび硫黄−含有化合物、並びに該化合物の製造方法および使用方法 |
WO2005061468A1 (en) | 2003-12-17 | 2005-07-07 | Rib-X Pharmaceuticals, Inc. | Halogenated biaryl heterocyclic compounds and methods of making and using the same |
KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
EP1778653A1 (en) | 2004-07-28 | 2007-05-02 | Rib-X Pharmaceuticals, Inc. | Biaryl heterocyclic compounds and methods of making and using the same |
EP2816033A1 (en) | 2004-07-30 | 2014-12-24 | Abbvie Inc. | Preparation of pyridonecarboxylic acid antibacterials |
PT3056492T (pt) | 2004-10-08 | 2021-12-27 | Abbvie Inc | Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina) |
CA2603783C (en) | 2005-04-11 | 2014-11-18 | Abbott Laboratories | Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs |
US20070238719A1 (en) | 2005-05-10 | 2007-10-11 | Hopkins Scott J | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures |
US20070249577A1 (en) | 2005-05-10 | 2007-10-25 | Hopkins Scott J | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures |
AU2009314072C1 (en) | 2008-11-15 | 2016-11-10 | Melinta Subsidiary Corp. | Antimicrobial compositions |
WO2010096551A2 (en) | 2009-02-18 | 2010-08-26 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compositions |
US20110281839A1 (en) | 2010-05-17 | 2011-11-17 | Peterson Janet | Combination therapy for the treatment of bacterial infections |
-
2014
- 2014-03-14 MX MX2015011760A patent/MX2015011760A/es unknown
- 2014-03-14 EP EP14768456.7A patent/EP2969004A4/en active Pending
- 2014-03-14 JP JP2016502372A patent/JP6617097B2/ja active Active
- 2014-03-14 TW TW103109491A patent/TWI641372B/zh active
- 2014-03-14 US US14/775,465 patent/US12036219B2/en active Active
- 2014-03-14 AU AU2014239965A patent/AU2014239965A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/027220 patent/WO2014152332A1/en active Application Filing
- 2014-03-14 BR BR112015023044A patent/BR112015023044A8/pt not_active Application Discontinuation
- 2014-03-14 CA CA2904387A patent/CA2904387C/en active Active
- 2014-03-14 KR KR1020157029301A patent/KR102237887B1/ko active IP Right Grant
- 2014-03-17 AR ARP140101219A patent/AR095594A1/es unknown
-
2015
- 2015-09-03 IL IL241113A patent/IL241113A0/en unknown
- 2015-09-15 CL CL2015002759A patent/CL2015002759A1/es unknown
-
2016
- 2016-06-30 HK HK16107660.6A patent/HK1219690A1/zh unknown
-
2019
- 2019-01-24 AU AU2019200483A patent/AU2019200483A1/en not_active Abandoned
- 2019-07-26 JP JP2019137649A patent/JP2019196401A/ja active Pending
-
2021
- 2021-08-19 US US17/406,805 patent/US20220257584A1/en not_active Abandoned
-
2023
- 2023-05-26 US US18/324,754 patent/US20240165100A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20150133762A (ko) | 2015-11-30 |
AU2019200483A1 (en) | 2019-02-14 |
JP6617097B2 (ja) | 2019-12-04 |
US20160058750A1 (en) | 2016-03-03 |
BR112015023044A2 (pt) | 2017-07-18 |
AU2014239965A1 (en) | 2015-09-24 |
MX2015011760A (es) | 2016-06-10 |
HK1219690A1 (zh) | 2017-04-13 |
US20240165100A1 (en) | 2024-05-23 |
US12036219B2 (en) | 2024-07-16 |
TW201513862A (zh) | 2015-04-16 |
US20220257584A1 (en) | 2022-08-18 |
EP2969004A1 (en) | 2016-01-20 |
CL2015002759A1 (es) | 2016-04-22 |
EP2969004A4 (en) | 2016-09-21 |
KR102237887B1 (ko) | 2021-04-07 |
CA2904387A1 (en) | 2014-09-25 |
IL241113A0 (en) | 2015-11-30 |
JP2016513689A (ja) | 2016-05-16 |
BR112015023044A8 (pt) | 2021-09-28 |
TWI641372B (zh) | 2018-11-21 |
CA2904387C (en) | 2021-12-07 |
JP2019196401A (ja) | 2019-11-14 |
WO2014152332A1 (en) | 2014-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2014000043A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
CA2909335C (en) | Fenfluramine for use in the treatment of dravet syndrome | |
AR089993A1 (es) | Macrociclos peptidomimeticos | |
UY33396A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
UY35693A (es) | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso | |
GT201600002A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
CL2015002677A1 (es) | Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial. | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
CL2015003019A1 (es) | Derivados biaromáticos antibacterianos | |
WO2019040106A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
EA201690964A1 (ru) | Композиции и способы для уменьшения серьезных неблагоприятных сердечно-сосудистых явлений | |
CL2015002346A1 (es) | Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
UY33993A (es) | Análogo macrocíclico de la sangliferina y su método de producción | |
AR095594A1 (es) | Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos | |
UY36173A (es) | Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia | |
UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
UY35610A (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
CO2019011227A2 (es) | N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso | |
EA201790220A1 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией | |
AR098614A1 (es) | Compuesto para el tratamiento de hipoglicemia severa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |